KYMERA THERAPEUTICS, INC. Other Nonoperating Income (Expense)
KYMERA THERAPEUTICS, INC. (KYMR) reported Other Nonoperating Income (Expense) of $14.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:OtherNonoperatingIncomeExpense · last filed 2026-08-05
- KYMERA THERAPEUTICS, INC. other nonoperating income (expense) for the quarter ending 2026-06-30 was $14.40M, a 81.24% increase year-over-year.
- KYMERA THERAPEUTICS, INC. other nonoperating income (expense) for the quarter ending 2026-03-31 was $14.92M, a 68.68% increase year-over-year.
- KYMERA THERAPEUTICS, INC. other nonoperating income (expense) for the quarter ending 2025-12-31 was $10.91M, a 9.12% increase year-over-year.
- KYMERA THERAPEUTICS, INC. other nonoperating income (expense) for the quarter ending 2025-09-30 was $10.35M, a 7.36% increase year-over-year.
- KYMERA THERAPEUTICS, INC. other nonoperating income (expense) for fiscal 2025 was $38.05M, a 0.72% increase from fiscal 2024.
- KYMERA THERAPEUTICS, INC. other nonoperating income (expense) for fiscal 2024 was $37.78M, a 103.45% increase from fiscal 2023.
- KYMERA THERAPEUTICS, INC. other nonoperating income (expense) for fiscal 2023 was $18.57M, a 187.97% increase from fiscal 2022.
- KYMERA THERAPEUTICS, INC. other nonoperating income (expense) for fiscal 2022 was $6.45M, a 1960.06% increase from fiscal 2021.
| Period end | Other Nonoperating Income (Expense) 3 month | Other Nonoperating Income (Expense) 6 month | Other Nonoperating Income (Expense) 9 month | Other Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.40M 10-Q · filed 2026-08-05 | $29.32M 10-Q · filed 2026-08-05 | $40.23M derived: sum of 3 quarters · filed 2026-08-05 | $50.58M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $14.92M 10-Q · filed 2026-04-30 | $25.84M derived: sum of 2 quarters · filed 2026-04-30 | $36.18M derived: sum of 3 quarters · filed 2026-04-30 | $44.12M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $10.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $21.26M derived: sum of 2 quarters · filed 2026-02-26 | $29.20M derived: sum of 3 quarters · filed 2026-08-05 | $38.05M 10-K · filed 2026-02-26 |
| 2025-09-30 | $10.35M 10-Q · filed 2025-11-04 | $18.29M derived: sum of 2 quarters · filed 2026-08-05 | $27.13M 10-Q · filed 2025-11-04 | $37.14M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $7.94M 10-Q · filed 2026-08-05 | $16.79M 10-Q · filed 2026-08-05 | $26.79M derived: sum of 3 quarters · filed 2026-08-05 | $36.43M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $8.85M 10-Q · filed 2026-04-30 | $18.85M derived: sum of 2 quarters · filed 2026-04-30 | $28.48M derived: sum of 3 quarters · filed 2026-04-30 | $37.35M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $10.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $19.64M derived: sum of 2 quarters · filed 2026-02-26 | $28.50M derived: sum of 3 quarters · filed 2026-02-26 | $37.78M 10-K · filed 2026-02-26 |
| 2024-09-30 | $9.64M 10-Q · filed 2025-11-04 | $18.50M derived: sum of 2 quarters · filed 2025-11-04 | $27.77M 10-Q · filed 2025-11-04 | $32.72M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $8.86M 10-Q · filed 2025-08-11 | $18.14M 10-Q · filed 2025-08-11 | $23.08M derived: sum of 3 quarters · filed 2026-02-26 | $27.72M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $9.27M 10-Q · filed 2025-05-09 | $14.22M derived: sum of 2 quarters · filed 2026-02-26 | $18.86M derived: sum of 3 quarters · filed 2026-02-26 | $23.44M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $4.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $9.59M derived: sum of 2 quarters · filed 2026-02-26 | $14.17M derived: sum of 3 quarters · filed 2026-02-26 | $18.57M 10-K · filed 2026-02-26 |
| 2023-09-30 | $4.64M 10-Q · filed 2024-10-31 | $9.23M derived: sum of 2 quarters · filed 2024-10-31 | $13.62M 10-Q · filed 2024-10-31 | $17.39M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $4.58M 10-Q · filed 2024-08-07 | $8.98M 10-Q · filed 2024-08-07 | $12.75M derived: sum of 3 quarters · filed 2025-02-27 | $14.63M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $4.40M 10-Q · filed 2024-05-02 | $8.16M derived: sum of 2 quarters · filed 2025-02-27 | $10.04M derived: sum of 3 quarters · filed 2025-02-27 | $10.60M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $3.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $5.64M derived: sum of 2 quarters · filed 2025-02-27 | $6.20M derived: sum of 3 quarters · filed 2025-02-27 | $6.45M 10-K · filed 2025-02-27 |
| 2022-09-30 | $1.88M 10-Q · filed 2023-11-02 | $2.43M derived: sum of 2 quarters · filed 2023-11-02 | $2.68M 10-Q · filed 2023-11-02 | $2.78M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $553.00K 10-Q · filed 2023-08-03 | $803.00K 10-Q · filed 2023-08-03 | $896.00K derived: sum of 3 quarters · filed 2024-02-22 | $951.00K derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $249.00K 10-Q · filed 2023-05-04 | $343.00K derived: sum of 2 quarters · filed 2024-02-22 | $398.00K derived: sum of 3 quarters · filed 2024-02-22 | $468.00K derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $94.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $149.00K derived: sum of 2 quarters · filed 2024-02-22 | $219.00K derived: sum of 3 quarters · filed 2024-02-22 | $313.00K 10-K · filed 2024-02-22 |
| 2021-09-30 | $55.00K 10-Q · filed 2022-11-03 | $125.00K derived: sum of 2 quarters · filed 2022-11-03 | $219.00K 10-Q · filed 2022-11-03 | $316.00K derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $70.00K 10-Q · filed 2022-08-09 | $164.00K 10-Q · filed 2022-08-09 | $261.00K derived: sum of 3 quarters · filed 2023-02-23 | $358.00K derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $94.00K 10-Q · filed 2022-05-03 | $191.00K derived: sum of 2 quarters · filed 2023-02-23 | $288.00K derived: sum of 3 quarters · filed 2023-02-23 | $491.00K derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $97.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $194.00K derived: sum of 2 quarters · filed 2023-02-23 | $397.00K derived: sum of 3 quarters · filed 2023-02-23 | $711.00K 10-K · filed 2023-02-23 |
| 2020-09-30 | $97.00K 10-Q · filed 2021-11-10 | $300.00K derived: sum of 2 quarters · filed 2021-11-10 | $614.00K 10-Q · filed 2021-11-10 | $885.00K derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $203.00K 10-Q · filed 2021-08-06 | $518.00K 10-Q · filed 2021-08-06 | $788.00K derived: sum of 3 quarters · filed 2022-02-24 | $1.23M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $315.00K 10-Q · filed 2021-05-06 | $585.00K derived: sum of 2 quarters · filed 2022-02-24 | $1.03M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2019-12-31 | $270.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $711.00K derived: sum of 2 quarters · filed 2022-02-24 | $959.00K 10-K · filed 2022-02-24 | |
| 2019-09-30 | $441.00K 10-Q · filed 2020-11-05 | $689.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |